TY - JOUR
T1 - Effects of Prebiotics vs a Diet Low in FODMAPs in Patients With Functional Gut Disorders
AU - Huaman, Jose Walter
AU - Mego, Marianela
AU - Manichanh, Chaysavanh
AU - Cañellas, Nicolau
AU - Cañueto, Daniel
AU - Segurola, Hegoi
AU - Jansana, Marta
AU - Malagelada, Carolina
AU - Accarino, Anna
AU - Vulevic, Jelena
AU - Tzortzis, George
AU - Gibson, Glenn
AU - Saperas, Esteban
AU - Guarner, Francisco
AU - Azpiroz, Fernando
PY - 2018/10/1
Y1 - 2018/10/1
N2 - © 2018 AGA Institute Prebiotics and diets low in fermentable oligo-, di-, mono-saccharides and polyols (low-FODMAP diet) might reduce symptoms in patients with functional gastrointestinal disorders, despite reports that some nonabsorbable, fermentable meal products (prebiotics) provide substrates for colonic bacteria and thereby increase gas production. We performed a randomized, parallel, double-blind study of patients with functional gastrointestinal disorders with flatulence. We compared the effects of a prebiotic supplement (2.8 g/d Bimuno containing 1.37 g beta-galactooligosaccharide) plus a placebo (Mediterranean-type diet (prebiotic group, n = 19) vs a placebo supplement (2.8 g xylose) plus a diet low in FODMAP (low-FODMAP group, n = 21) for 4 weeks; patients were then followed for 2 weeks. The primary outcome was effects on composition of the fecal microbiota, analyzed by 16S sequencing. Secondary outcomes were intestinal gas production and digestive sensations. After 4 weeks, we observed opposite effects on microbiota in each group, particularly in relation to the abundance of Bifidobacterium sequences (increase in the prebiotic group and decrease in the low-FODMAP group; P =.042), and Bilophila wadsworthia (decrease in the prebiotic group and increase in the low-FODMAP group; P =.050). After 4 weeks, both groups had statistically significant reductions in all symptom scores, except reductions in flatulence and borborygmi were not significant in the prebiotic group. Although the decrease in symptoms persisted for 2 weeks after patients discontinued prebiotic supplementation, symptoms reappeared immediately after patients discontinued the low-FODMAP diet. Intermittent prebiotic administration might therefore be an alternative to dietary restrictions for patients with functional gut symptoms. ClinicalTrials.gov no.: NCT02210572.
AB - © 2018 AGA Institute Prebiotics and diets low in fermentable oligo-, di-, mono-saccharides and polyols (low-FODMAP diet) might reduce symptoms in patients with functional gastrointestinal disorders, despite reports that some nonabsorbable, fermentable meal products (prebiotics) provide substrates for colonic bacteria and thereby increase gas production. We performed a randomized, parallel, double-blind study of patients with functional gastrointestinal disorders with flatulence. We compared the effects of a prebiotic supplement (2.8 g/d Bimuno containing 1.37 g beta-galactooligosaccharide) plus a placebo (Mediterranean-type diet (prebiotic group, n = 19) vs a placebo supplement (2.8 g xylose) plus a diet low in FODMAP (low-FODMAP group, n = 21) for 4 weeks; patients were then followed for 2 weeks. The primary outcome was effects on composition of the fecal microbiota, analyzed by 16S sequencing. Secondary outcomes were intestinal gas production and digestive sensations. After 4 weeks, we observed opposite effects on microbiota in each group, particularly in relation to the abundance of Bifidobacterium sequences (increase in the prebiotic group and decrease in the low-FODMAP group; P =.042), and Bilophila wadsworthia (decrease in the prebiotic group and increase in the low-FODMAP group; P =.050). After 4 weeks, both groups had statistically significant reductions in all symptom scores, except reductions in flatulence and borborygmi were not significant in the prebiotic group. Although the decrease in symptoms persisted for 2 weeks after patients discontinued prebiotic supplementation, symptoms reappeared immediately after patients discontinued the low-FODMAP diet. Intermittent prebiotic administration might therefore be an alternative to dietary restrictions for patients with functional gut symptoms. ClinicalTrials.gov no.: NCT02210572.
KW - Functional Intestinal Disorders
KW - Intestinal Gas
KW - Microbiota
UR - https://www.scopus.com/pages/publications/85054188547
U2 - 10.1053/j.gastro.2018.06.045
DO - 10.1053/j.gastro.2018.06.045
M3 - Article
C2 - 29964041
SN - 0016-5085
VL - 155
SP - 1004
EP - 1007
JO - Gastroenterology
JF - Gastroenterology
IS - 4
ER -